Announcements
Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Original Research
Use of intramyometrial injection of prostaglandin F2α in the management of intractable hemorrhage due to uterine atony
Show Less
1
Department of Obstetrics and Gynecology, University of Padua
2
Institute of Anaesthesiology and Resuscitation, University of Padua (Italy)
Clin. Exp. Obstet. Gynecol. 1982, 9(1), 26–30;
Published: 10 March 1982
Abstract
Prostaglandin F2α, in doses varying from 1 to 5 mg was injected transabdominally, transvaginally or intraabdominally (during caesarean section) into the myometrium in ten patients affected by metrorrhagias not responsive to conventional uterotonic drugs. In all cases but one the result was excellent. Important side effects were observed in only one patient, because of the inadvertent intravascular injection of 5 mg Prostaglandin into the endocervix. An adequate treatment of this patient brought her to complete recovery in a short time. According to our experience, the intramyometrial injection of PGF2α, in doses varying from 1 to 2 mg, is a simple, safe and effective method in the control of severe hemorrhage due to uterine atony not responding to conventional treatment.